Aeglea Biotherapeutics Inc. (NASDAQ:AGLE) has been assigned a consensus broker rating score of 1.33 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company.
Analysts have set a 12 month consensus price objective of $18.50 for the company and are predicting that the company will post ($0.67) EPS for the current quarter, according to Zacks. Zacks has also given Aeglea Biotherapeutics an industry rank of 107 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research raised Aeglea Biotherapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, September 13th.
Shares of Aeglea Biotherapeutics (NASDAQ:AGLE) opened at 6.84 on Wednesday. The firm’s market capitalization is $91.73 million. The stock has a 50 day moving average price of $6.60 and a 200-day moving average price of $6.59. Aeglea Biotherapeutics has a 52 week low of $3.89 and a 52 week high of $12.75.
Aeglea Biotherapeutics (NASDAQ:AGLE) last posted its earnings results on Tuesday, August 9th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by $0.03. On average, equities research analysts forecast that Aeglea Biotherapeutics will post ($4.77) earnings per share for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. VHCP Management II LLC purchased a new stake in Aeglea Biotherapeutics during the second quarter valued at about $1,527,000. Ghost Tree Capital LLC purchased a new stake in Aeglea Biotherapeutics during the second quarter valued at about $243,000. Finally, Perceptive Advisors LLC purchased a new stake in Aeglea Biotherapeutics during the second quarter valued at about $515,000. 40.71% of the stock is currently owned by institutional investors and hedge funds.
Aeglea Biotherapeutics Company Profile
Aeglea BioTherapeutics, Inc is a biotechnology company. The Company is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its engineered human enzymes are designed to degrade specific amino acids in the blood.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aeglea Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.